Surya Seshan, MD
Pathology · New York, NYNPI 1457382061
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,713 of the $69,174 with a category attached, or 99.3%. Astrazeneca UK Limited accounts for 99.3% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $67,050, more than ten times the $90 reported in 2019. Among pathology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 8 payments — averaging $8646.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$69K
- AstraZeneca$296
- Mallinckrodt Enterprises LLC$90
- Novartis$75
Across 2 payments — averaging $10,676 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$21K
What the payments were for
- Consulting fees$68,71399%
- Food & beverage$3711%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 4 | $68,713 |
| AstraZeneca | 2 | $296 |
| Mallinckrodt Enterprises LLC | 1 | $90 |
| Novartis | 1 | $75 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$69,174 in reported general payments places this provider in the 95th percentile of 448 pathology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pathology in New York
- Marina LandaNew York$42
- Iskender GencoNew York$27
- Christopher HaleNew York$23
- Yansheng HaoNew York$15
- Tilla PohlNew York$0
- Beatriz Caraballo BordonNew York$0
- Matthew ShapiroNew York$0
- Shih-Hsiu WangNew York$0
- Alan MarcusNew York$0
- Codrin IacobNew York$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.